23,534 Shares in uniQure (NASDAQ:QURE) Purchased by Ballentine Partners LLC

Ballentine Partners LLC acquired a new position in uniQure (NASDAQ:QURE) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 23,534 shares of the biotechnology company’s stock, valued at approximately $116,000.

A number of other hedge funds have also recently modified their holdings of QURE. Vanguard Personalized Indexing Management LLC lifted its stake in shares of uniQure by 21.0% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 2,306 shares during the last quarter. American Century Companies Inc. lifted its position in shares of uniQure by 14.6% during the second quarter. American Century Companies Inc. now owns 67,699 shares of the biotechnology company’s stock worth $303,000 after purchasing an additional 8,642 shares during the last quarter. Clear Harbor Asset Management LLC boosted its stake in shares of uniQure by 35.2% during the second quarter. Clear Harbor Asset Management LLC now owns 48,000 shares of the biotechnology company’s stock valued at $215,000 after purchasing an additional 12,500 shares during the period. Cubist Systematic Strategies LLC grew its holdings in shares of uniQure by 130.9% in the second quarter. Cubist Systematic Strategies LLC now owns 25,494 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 14,454 shares during the last quarter. Finally, Total Clarity Wealth Management Inc. purchased a new position in uniQure in the 2nd quarter worth about $74,000. Institutional investors own 78.83% of the company’s stock.

uniQure Trading Down 1.8 %

QURE opened at $6.31 on Thursday. The company has a current ratio of 7.36, a quick ratio of 7.36 and a debt-to-equity ratio of 1.06. The firm has a market cap of $307.05 million, a price-to-earnings ratio of -1.06 and a beta of 0.95. uniQure has a 12 month low of $3.73 and a 12 month high of $11.35. The stock has a fifty day moving average price of $5.72 and a 200-day moving average price of $5.74.

uniQure (NASDAQ:QURE) last posted its earnings results on Thursday, August 1st. The biotechnology company reported ($1.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.24) by $0.08. The company had revenue of $11.13 million for the quarter, compared to analyst estimates of $3.47 million. uniQure had a negative return on equity of 158.09% and a negative net margin of 1,027.52%. As a group, equities research analysts anticipate that uniQure will post -4.1 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have issued reports on QURE. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of uniQure in a research report on Tuesday, August 20th. Raymond James reissued an “outperform” rating and issued a $20.00 price objective on shares of uniQure in a research note on Thursday, October 10th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $28.00 target price on shares of uniQure in a research report on Friday, September 20th. StockNews.com raised uniQure to a “sell” rating in a research report on Thursday, October 17th. Finally, The Goldman Sachs Group lifted their price objective on uniQure from $6.00 to $10.00 and gave the company a “neutral” rating in a report on Friday, August 2nd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, uniQure has a consensus rating of “Hold” and a consensus target price of $19.50.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.